US · Healthcare · Diagnostics & Research
EPS came in at -0.01 against a street estimate of -0.06 — a beat of 83.3%.
Analysts rate NeoGenomics Inc a buy (8 buy, 4 hold, 0 sell out of 12) with an average price target of $19.72.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.53% |
| First Light Asset Management, LLC | 7.57% |
| Greenhouse Funds LLLP | 7.08% |
| Vanguard Portfolio Management, LLC | 5.93% |
| First Trust Advisors L.P. | 4.80% |
| Vanguard Capital Management, LLC | 4.40% |
| BRAIDWELL LP | 4.37% |
| State Street Corp | 3.99% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-28 |
| Results announced · Q3 2026 | 2026-07-28 |
| Reg FD disclosure · Q3 2026 | 2026-07-20 |
| Board / officer change · Q2 2026 | 2026-06-25 |
| Material agreement · Q2 2026 | 2026-06-22 |
| Quarterly report · Q1 2026 | 2026-04-28 |
| Proxy statement · Q4 2025 | 2026-04-06 |
| Annual report FY2025 | 2026-02-17 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for NeoGenomics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.